Latest Period
Q4 2025
Security Snapshot
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) Institutional Ownership
CUSIP: 09075P204
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
42
Shares (Excl. Options)
3,538,520
Price
$1.60
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- BTAI on Nasdaq
- Shares outstanding
- 21,847,524
- Price per share
- $1.02
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 3,538,520
- Total reported value
- $5,667,324
- % of total 13F portfolios
- 0%
- Share change
- +1,195,942
- Value change
- +$1,743,166
- Number of holders
- 42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 09075P204.
- 42 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 42 to 15 between Q4 2025 and Q1 2026.
- Reported value moved from $5,667,324 to $556,269.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 42 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 09075P204?
CUSIP 09075P204 identifies BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 09075P204:
Significant Owners of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| INTEGRATED CORE STRATEGIES (US) LLC | 8.4% | +64% | $3,762,144 | +$1,654,635 | 1,835,192 | +79% | Millennium Management LLC | 31 Dec 2025 |
| ARMISTICE CAPITAL, LLC | 5% | -50% | $564,737 | -$9,229,922 | 288,131 | -94% | Armistice Capital, LLC | 31 Mar 2025 |
As of 31 Dec 2025, 42 institutional investors reported holding 3,538,520 shares of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI). This represents 16% of the company’s total 21,847,524 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) together control 16% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 8.4% | 1,835,192 | +79% | 0% | $2,936,307 |
| VANGUARD GROUP INC | 1.3% | 292,753 | +52% | 0% | $468,405 |
| OAKTREE CAPITAL MANAGEMENT LP | 1.1% | 241,188 | 0% | 0.01% | $385,902 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.94% | 206,168 | +65% | 0% | $329,873 |
| JONES FINANCIAL COMPANIES LLLP | 0.63% | 137,690 | +282% | 0% | $220,304 |
| JANE STREET GROUP, LLC | 0.58% | 127,501 | 0% | $204,002 | |
| GSA CAPITAL PARTNERS LLP | 0.55% | 120,102 | 0.02% | $192,000 | |
| FMR LLC | 0.41% | 90,300 | -55% | 0% | $144,480 |
| BlackRock, Inc. | 0.39% | 84,396 | +0.14% | 0% | $135,033 |
| STATE STREET CORP | 0.29% | 63,218 | +20% | 0% | $101,149 |
| Man Group plc | 0.26% | 56,825 | 0% | $90,920 | |
| Oaktree Fund Advisors, LLC | 0.2% | 42,913 | 0% | 0.13% | $68,660 |
| HighTower Advisors, LLC | 0.19% | 41,000 | +17% | 0% | $65,600 |
| NORTHERN TRUST CORP | 0.18% | 38,370 | +1.7% | 0% | $61,392 |
| UBS Group AG | 0.18% | 38,340 | -12% | 0% | $61,344 |
| HRT FINANCIAL LP | 0.08% | 18,062 | 0% | $28,000 | |
| TWO SIGMA SECURITIES, LLC | 0.08% | 17,068 | 0% | $27,309 | |
| OSAIC HOLDINGS, INC. | 0.07% | 15,749 | +131142% | 0% | $25,197 |
| DIVERSIFY WEALTH MANAGEMENT, LLC | 0.07% | 15,000 | 0% | 0% | $30,750 |
| Engineers Gate Manager LP | 0.06% | 12,303 | 0% | $19,685 | |
| Portfolio Strategies, Inc. | 0.06% | 12,178 | 0% | $19,485 | |
| CITIGROUP INC | 0.06% | 12,079 | +3303% | 0% | $19,326 |
| IFP Advisors, Inc | 0.02% | 4,370 | 0% | 0% | $6,992 |
| WELLS FARGO & COMPANY/MN | 0.02% | 4,325 | -73% | 0% | $6,920 |
| GROUP ONE TRADING LLC | 0.01% | 3,185 | +42% | 0% | $5,096 |
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 418,486 | $556,269 | -$404,452 | $1.34 | 15 |
| 2025 Q4 | 3,538,520 | $5,667,324 | +$1,743,166 | $1.60 | 42 |
| 2025 Q3 | 2,342,780 | $5,992,669 | +$4,499,749 | $2.56 | 35 |
| 2025 Q2 | 603,081 | $1,090,541 | +$395,829 | $1.81 | 33 |
| 2025 Q1 | 378,983 | $769,811 | +$769,716 | $2.03 | 31 |